powerballwinningnumberstonight| Dividend resource products and new productivity have become the focus! What signals did China-Europe Funds Lan Xiaokang, Ge Lan and Liu Weiwei reveal in their quarterly reports?
The annual report season is just over.PowerballwinningnumberstonightThe public offering fund made its debut again in its quarterly report. Since the Spring Festival, the A-share market has picked up, with the Shanghai Composite Index up 2% in the first quarter.Powerballwinningnumberstonight.23%, the CSI 300 index rose 3%.Powerballwinningnumberstonight.1%, driving the net value of the fund also ushered in an upward trend. According to the quarterly report disclosed by the China Europe Fund, funds such as China Europe Ruifeng managed by Lu Chunqing and China Europe dividend Superior managed by Blue well-off have allocated dividend and resource assets in advance and reaped significant excess returns.PowerballwinningnumberstonightSeizing the opportunity of low layout, a number of new bases, such as the win-win situation of the China-Europe era, the China-Europe China Robot Index Fund and the China-Europe China Chip Industry Index Fund, have also ushered in a beautiful net worth curve.
From the point of view of the Quarterly report, Lan Xiaokang believes that the opportunities for resource products will continue to be interpreted. "We are optimistic about dividend and resource stocks to increase our attention to state-owned enterprises." Glenn, the manager of CEIBS Health Fund, is still optimistic about the innovation-driven pharmaceutical industry chain and pays attention to innovation and opportunities for going out to sea. Liu Weiwei makes a long-term layout around the new quality productive forces from four major directions related to science and technology.
Keep an eye on resource dividend stocks! Blue well-off: dividend values will be more important
In the first quarter of this year, the stock price of resource products was eye-catching, and dividend-themed funds ushered in a bumper harvest. According to the quarterly report, over the past year, the net growth rate of China-EU dividend preferred flexible allocation mixed A reached 3.34%, exceeding the performance benchmark by 11.39 percentage points. 'The strong performance of resource stocks so far this year confirms our judgment over the past two years,'he said in his quarterly report. "Macroeconomic aggregate faces challenges under anti-globalization, but the shift of economic structure to manufacturing makes physical consumption resilient. The supply of mineral resources in the upper reaches is faced with many constraints such as underinvestment, environmental protection, labor and so on, so the high price and high profit of resources are expected to be maintained for a long time. Therefore, we will continue to invest in resource stocks. For gold assets, from a long-term perspective, it can not only contribute to earnings, but also is expected to guard against the potential risk of high debt in the US dollar. "
Although the dividend strategy is also facing concerns about overcrowding, Lan Xiaokang believes that dividend assets are still worthy of attention. "just like when people bought sustainable assets four or five years ago, the return on stock prices is not the 20% increase of 30% in the current year, and the return on dividend stocks is not necessarily just the dividend of that year. From the asset map of the whole society, the assets of dividend shares are attractive, and the value of dividend will be more important in the values of the stock market. " He said.
At the end of the quarterly report, Lan Xiaokang maintained a relatively optimistic judgment on the market in 2024, believing that investors' risk appetite is still low and that economic recovery is expected to enhance the consumption willingness of the whole society and the risk appetite of investors. Specific to the industry, he is optimistic about the investment opportunities of excellent companies in non-ferrous metals, machinery, coal, petroleum and petrochemical, transportation, construction, banking, non-bank, steel, tourism, catering, media and other industries.
Innovation drives the medical industry chain! Glenn: actively pay attention to innovation and going out to sea
Looking back on the first quarter, the pharmaceutical sector is still in the shock adjustment stage. The Shenwan Pharmaceutical Biological Index fell 12.08% in the first quarter, ranking at the bottom of the Shenxian industry index. From the perspective of industry fundamentals, different segments of the industry are in different profit cycles, but the overall performance is stable and at the undervalued stage; from the policy level, the main direction is still to guide the provision of "highly innovative", "high clinical value" and "cost-effective" products and services, and the newly announced insulin special succession rules are generally moderate. From the perspective of the pattern of supply and demand, under the environment of overall stabilization of domestic demand, the demand for medical insurance payment and residents' diversified medical and health expenditure is still showing a certain rigidity, and the supply side is undergoing a reshuffle and optimization in the trough period. the core competitiveness of high-quality enterprises and the moat are also being strengthened.
Looking forward to the second quarter, Glenn said in the quarterly report that he is still optimistic about the innovation-driven pharmaceutical industry chain. "as an important part of the new quality productivity, pharmaceutical innovation is also the most firm direction of enterprise layout. The number of varieties applying for listing of chemical drugs, biological drugs and traditional Chinese medicine innovative drugs continues to increase in 2023, and it is expected to usher in the peak period of approval and listing of related innovative drugs in 2024. "
She also said bluntly in the quarterly report that the development of the domestic innovative drug industry chain is facing certain twists and turns and complexity. The healthy and sustainable development of the industrial chain needs unified coordination from many aspects, such as enterprise financing, product project establishment, R & D promotion, registration application, entering hospital purchase catalogue, compliance sales, health insurance payment and so on. In view of the pain points of each link of the industrial chain, in recent years, the national level has continued to carry out scientific overall planning and precise dredging through policies and measures, and the overall guiding direction of the industrial chain is still a real innovation. mainly reflected in new targets, new mechanisms, new structures, new technologies and drugs with independent intellectual property rights, as well as effective treatments to meet clinical needs. Predictably, the support and guidance at the national policy level is expected to lead to a new round of healthier and sustainable R & D cycle, which also contains opportunities worthy of advance layout.
In terms of the medical industry chain going out to sea, Glenn said that with the continuous advancement of the international level in the field of medical devices, some enterprises have gradually made international breakthroughs in the field of high value chain and occupied overseas market opportunities, mainly focused on innovative equipment, in vitro diagnosis and other fields. Although the internationalization process of some enterprises will be affected by the periodic changes of the global geopolitical situation, the long-term core competitiveness of high-quality assets in the domestic innovation industry chain has not changed.
The rise of new quality productive forces! Liu Weiwei: be optimistic about the four directions related to innovation
As one of the first floating rate products in the market, CEIBS win-win was established on November 28, 2023. It significantly increased its stock position in the first quarter of this year and gained a bright net worth curve. "our portfolio substantially outperformed the performance benchmark in the first quarter, partly because of the Jiancang time point, and partly because of the large rebound in the industries and stocks we allocated." Liu Weiwei said in the quarterly report.
In the quarterly report, Liu Weiwei mentioned the understanding of the new quality productivity, "the new quality productivity and scientific and technological innovation are inseparable." Therefore, at the industrial level, we also focus on four major directions related to innovation: technology, photovoltaic energy storage, smart cars and innovative drugs. "
Specifically, he said that in the field of science and technology, technological breakthroughs represented by AI are expected to spread from computing infrastructure to applications, hardware terminals such as PC, mobile phones and AIOT are expected to bring forth new ideas, and the science and technology industry is still leading the trend of the times. Autopilot and humanoid robot are the integration of AI technology and advanced manufacturing. Rapid progress has been made at home and abroad. The strong advantages of China's manufacturing industry will still enable us to take the lead in these two fields.
In the field of photovoltaic energy storage, "with the rapid decline in the prices of photovoltaic modules, batteries and other products, the global integration of photovoltaic storage is expected to gradually usher in parity, thus driving the industry to enter a new round of development." Liu Weiwei said.
In terms of innovative drugs, he believes that weight-loss drugs, Alzheimer's disease and ADC have also gradually begun to enter the process of commercialization in the past two years, and the innovation of the pharmaceutical industry is entering a new upsurge.
Source of index data: wind, statistical range: 2024-1-1-2024-3-31.
Performance data are derived from the periodic report of the Fund as of 2024-3-31. The past performance of the fund does not predict its future performance, and the performance of other funds managed by fund managers does not constitute a guarantee of fund performance. CEIBS dividend premium enjoys flexible configuration hybrid A up and down 74.1% since its inception, and the performance benchmark for the same period is-1.88%. In 2019-2023, the rise and fall of the fund and the benchmark performance for the same period were 43.27% 17.48% 25.77% 7.24% 27.63% 7.58% mai 10.2% mae Lei12% mai 2.92% gamma 6.84%. Successive fund managers: lan Xiaokang 20180420-Management so far, Cao Mingchang 20180419-20210210, Lubson 20180419-20200529. This product modifies the investment scope in 2020Compact 10 to add depositary receipts as the object of investment. Read the legal documents carefully.
The fund has risks and needs to be invested with caution. The fund manager undertakes to manage and use the fund assets in the principle of good faith and diligence, but does not guarantee the profit of the fund or the minimum return. The past performance of the fund does not predict its future performance, and the performance of other funds managed by fund managers does not constitute a guarantee of fund performance. Before you make an investment decision, please carefully read the product legal documents and risk disclosure books such as the fund contract, the fund prospectus and the summary of the fund product information, and fully understand the risk-return characteristics and product characteristics of the fund. seriously consider the various risk factors existing in the fund, and fully consider your risk tolerance according to your own investment purpose, investment period, investment experience, asset status and other factors. On the basis of understanding the product situation and sales appropriateness opinions, rational judgment and careful investment decisions are made. This fund is a mixed fund, and its expected return and expected risk level is higher than that of bond funds and money market funds, but lower than that of equity funds. The fund can invest in Hong Kong shares. In addition to the general investment risks such as market volatility risks similar to those of mainland securities investment funds, the Fund also faces unique risks caused by differences in the investment environment, investment targets, market systems and trading rules under the Hong Kong Stock Exchange mechanism.
Tags:
Prev: aliantebingo| How to calculate the partial rate of return formula i-the relationship between internal rate of return and other financial indicators
Next: crashbandicoot2017|. How to consider the impact of different benchmark rates of return on the internal rate of return? - Explore the ways in which different benchmark rates of return affect the internal rate of return